题名

抗新型冠狀病毒（SARS-CoV-2）口服藥物介紹

并列篇名

Oral Antiviral Treatments for COVID-19

DOI

10.6647/CN.202206_29(2).0010

作者

孫意惟(Yi-Wei Sun)；江德祐(De-You Jiang)；張闈墨(Wei-Mo Chang)

关键词

新型冠狀病毒 ； 口服藥 ； Paxlovid ； molnupiravir ； COVID-19 ； oral antiviral treatments ； Paxlovid ； molnupiravir

期刊名称

彰化護理

卷期/出版年月

29卷2期（2022 / 06 / 01）

页次

57 - 67

内容语文

繁體中文
中文摘要

截至2021年底已有兩種COVID-19口服抗病毒藥物問世，分別為Nirmatrelvir+ Ritonavir（Paxlovid®）及Molnupiravir（Lagevrio®），讓輕度至中度的確診患者有機會在家中就能獲得藥物治療。兩種口服藥物皆用於具任一重症風險因子，未使用氧氣且於發病五天內之COVID-19確診者；其中Paxlovid適用於12歲以上，而Lagevrio限用於18歲以上且臨床上不適用其他COVID-19治療選擇者。給藥時須注意兩者的服藥顆粒數不同，且因Paxlovid為CYP3A抑制劑，應特別小心藥物交互作用，並留意腎功能異常時需調整劑量。本文針對兩種抗新冠病毒口服藥物進行介紹與比較，並期待在不久的將來有更多對抗新冠病毒的藥物問世！
英文摘要

Two oral antiviral treatments for COVID-19 are available since 2021, including nirmatrelvir + ritonavir (Paxlovid®) and molnupiravir (Lagevrio®). Patients diagnosed with mild-to-moderate COVID-19 can be treated at home instead being hospitalized. When patients diagnosed with COVID-19 within five days, either Paxlovid or Lagevrio can be provided to whom without using oxygen, and at high risk for progression to severe COVID-19. Paxlovid is applicable for pediatric patients over 12 years of age, while Lagevrio is only available for adults who are not suitable for other treatments. It should be noticed that the number of tablets to take at once is different between the two. While Paxlovid contains a CYP3A inhibitor, drug-drug interactions should be considered. Furthermore, we should pay attention to patients' renal function for dosage adjustment when using Paxlovid. We introduced and made comparisons of the two oral treatments in this article and look forward to more antivirus treatments for COVID-19 in the future.
主题分类 醫藥衛生 > 預防保健與衛生學
醫藥衛生 > 社會醫學
参考文献
  1. COVID-19: Outpatient evaluation and management of acute illness in adults. UpToDate. Retrieved Feburary 18, 2022 from https://www.uptodate.com/contents/covid-19-outpatient-evaluation-and-management-of-acute-illness-in-adults
  2. Molnupiravir (United States: Authorized for use): Drug information. UpToDate. Retrieved Feburary 26, 2022 from https://www.uptodate.com/contents/molnupiravir-united-states-authorized-for-use-drug-information
  3. Nirmatrelvir and ritonavir: Drug information. UpToDate. Retrieved Feburary 24, 2022 from https://www.uptodate.com/contents/nirmatrelvir-and-ritonavir-united-states-and-canada-authorized-for-use-drug-information
  4. ClinicalTrials.gov. (February 4, 2022). Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection. (ClinicalTrials.gov Identifier: NCT05007236). https://www.clinicaltrials.gov/ct2/show/NCT05007236
  5. Hammond, J.,Leister-Tebbe, H.,Gardner, A.,Abreu, P.,Bao, W.,Wisemandle, W.,Rusnak, J. M.(2022).Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.New England Journal of Medicine,386(15),1397-1408.
  6. Institute for Safe Medication Practices. (January 4, 2022). ISMP Issues Warning about Possible Safety Issues with Newly-Authorized Paxlovid. https://www.ismp.org/news/ismp-issues-warning-about-possible-safety-issues-newly-authorized-Paxlovid
  7. Jayk Bernal, A.,Gomes da Silva, M. M.,Musungaie, D. B.,Kovalchuk, E.,Gonzalez, A.,Delos Reyes, V.,De Anda, C.(2022).Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.New England Journal of Medicine,386(6),509-520.
  8. National Institutes of Health. (December 30, 2021). The COVID-19 Treatment Guidelines Panel's Statement on Potential Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications. https://files.covid19treatmentguidelines.nih.gov/guidelines/section/section_164.pdf
  9. National Institutes of Health. (February 1, 2022). Therapeutic Management of Nonhospitalized Adults With COVID-19. https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/nonhospitalized-adults--therapeutic-management/
  10. National Institutes of Health. (February 24, 2022). Ritonavir-Boosted Nirmatrelvir (Paxlovid). https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ritonavir-boosted-nirmatrelvir--paxlovid-/
  11. Shionogi. (February 7, 2022). Shionogi Presents Phase 2/3 Clinical Trial Results (Phase 2a Part) for the COVID-19 Therapeutic Drug S-217622. https://www.shionogi.com/global/en/news/2022/2/e-20220207.html
  12. WHO. (2022). WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/
  13. 美商默沙東藥廠股份有限公司台灣分公司 (2022) ‧ Molnupiravir 醫療照護人員用藥說明 (2022 年 1 月 26 日版 ) 。https://www.chshb.gov.tw/sites/default/files/2022-05/%E9%BB%98%E6%B2%99%E6%9D%B1Molnupiravir%E4%B8%AD%E6%96%87%E8%AA%AA%E6%98%8E%E6%9B%B8%20%28%E5%90%AB%E7%97%85%E4%BA%BA%E8%88%87%E7%85%A7%E9%A1%A7%E8%80%85%E8%AA%AA%E6%98%8E%29.pdf
  14. 美商默沙東藥廠股份有限公司台灣分公司 (2022)‧Lagevrio藥品外觀。https://img.ltn.com.tw/Upload/health/page/800/2022/01/24/3811790_1.jpg
  15. 衛生福利部疾病管制署 (2022)‧新型冠狀病毒(SARS-CoV-2) 感染臨床處置暫行指引第十六版 。https://www.cdc.gov.tw/Category/Page/xCSwc5oznwcqunujPc-qmQ
  16. 衛生福利部疾病管制署(2022)‧公費COVID-19治療用口服抗病毒藥物領用方案 (111 年 1 月 26日訂定)。 https://www.cdc.gov.tw/File/Get/wWbiEQiJDKAgVI9S8I-SzQ
  17. 衛生福利部疾病管制署(2022年1月26日)‧SARS-CoV-2感染臨床處置暫行指引新增口服抗病毒藥物使用建議(疾病管制署致醫界通函第471 號）。 https://www.cdc.gov.tw/Bulletin/Detail/7LF3_zX-27ttBkfVRsjlqA?typeid=48
  18. 輝瑞大藥廠 (2022) ‧ Paxlovid 藥品外觀 。https://imgcdn.cna.com.tw/www/WebPhotos/800/20220127/959x636_0417787228.jpg
  19. 輝瑞大藥廠 (2022)‧PAXLOVID致醫療照護提供者的用藥說明書 (2022 年 1 月 2 6 日版 ) 。 https://www.cdc.gov.tw/Uploads/674c5828-fa27-43a1-bfbd-4a3d4755bee2.pdf
print cancel